Navigation Links
Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes
Date:6/10/2008

BEDFORD, Mass., June 10 /PRNewswire-FirstCall/ -- Insulet Corporation (the "Company") (Nasdaq: PODD) announced today that it has priced a private offering of $75 million in aggregate principal amount of its convertible senior notes due 2013 (the "notes") to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended. The Company has granted the initial purchasers an option to purchase up to an additional $10 million in aggregate principal amount of notes solely to cover over-allotments, if any.

The notes will pay interest semi-annually at a rate of 5.375% per annum and mature on June 15, 2013. The notes will have an initial conversion rate of 46.8467 shares of the Company's common stock per $1,000 principal amount of the notes, representing an initial conversion price of approximately $21.35 per share of common stock. Subject to customary closing conditions, the Company expects to close the offering on June 16, 2008.

The Company will use the net proceeds from the offering to repay and terminate its outstanding term loan and for general corporate purposes.

This notice does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offers of the notes will be made only by means of a private offering memorandum. The notes and any common stock of the Company issuable upon conversion of the notes have not been registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold absent registration or an applicable exemption from registration requirements.

This press release contains forward-looking statements concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the offering, the over-allotment option and the use of proceeds from the offering. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting it will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward- looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on the OmniPod System; the Company's ability to achieve and maintain market acceptance of the OmniPod System; potential manufacturing problems, including damage, destruction or loss of any of the Company's automated assembly units or difficulties in implementing its automated manufacturing strategy; potential problems with sole source or other third-party suppliers on which the Company is dependent; the Company's ability to obtain favorable reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; potential termination of the Company's license to incorporate a blood glucose meter into the OmniPod System; the Company's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the OmniPod System; the potential violation of federal or state laws prohibiting "kickbacks" and false and fraudulent claims or adverse affects of challenges to or investigations into the Company's practices under these laws; product liability lawsuits that may be brought against the Company; unfavorable results of clinical studies relating to the OmniPod System or the products of the Company's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to the Company's products; the Company's ability to attract and retain key personnel; the Company's ability to manage its growth; risks associated with potential future acquisitions; the Company's ability to successfully maintain effective internal controls; and other risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and in the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2008 and its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward- looking statements.

Contact:

Stephanie Marks for Insulet Corporation

ir@insulet.com

877-PODD-IR1 (877-763-3471)


'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
2. Insulet Corporation Announces Pricing of Secondary Public Offering
3. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
4. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
5. Insulet Corporation and DexCom Announce Development Agreement
6. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
7. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
8. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
9. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... Delta ... $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired as ... was the American Cancer Society’s 2015 CEO of the Year , helped lead ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
(Date:2/8/2016)... ... 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of ... of his birthday on February 10th. During this time, people can achieve better ... over 250,000 people from over 40 different countries as an “ordinary man with an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced ... with the tools and information to lower the costs, and increase the impact ... of providing employee healthcare benefits by as much as 22%:, + Price ...
(Date:2/6/2016)... ... 06, 2016 , ... Shark Finds and Kevin Harrington, along with ... DRTV campaign with Belly Bands. , Having a dog is great—except when it wets ... and find nothing works, get Belly Bands, the easiest way to stop dogs ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 /PRNewswire/ ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ... has announced the addition of the ... - Global Forecasts to 2020" report ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016  Unilife Corporation ("Unilife" ... and supplier of injectable drug delivery systems, today announced that ... six months ended December 31, 2015 after market close on ... scheduled a conference call to discuss these financial results.    ... Unilife Corporation --> About Unilife Corporation ...
(Date:2/8/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... the U.S. Food and Drug Administration (FDA) has ... for SB-318, a single treatment strategy intended to ... (MPS I). The SB-318 IND application is now ... 1/2 clinical study (SB-318-1502) designed to assess the ...
Breaking Medicine Technology: